Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 132

2.
3.

Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation.

Hakki M, Riddell SR, Storek J, Carter RA, Stevens-Ayers T, Sudour P, White K, Corey L, Boeckh M.

Blood. 2003 Oct 15;102(8):3060-7. Epub 2003 Jul 3.

4.

Management of allogeneic bone marrow transplant recipients at risk for cytomegalovirus disease using a surveillance bronchoscopy and prolonged pre-emptive ganciclovir therapy.

Reddy V, Hao Y, Lipton J, Meharchand J, Minden M, Mazzulli T, Chan C, Messner HA.

J Clin Virol. 1999 Aug;13(3):149-59.

PMID:
10443791
5.

Different kinetics in anti-cytomegalovirus immunity reconstitution evaluated by lymphocyte proliferation and IFN-gamma production in allogeneic and autologous bone marrow transplantation.

Mendes AV, Benard G, Pereira CB, Kallas EG, Duarte AJ, Pannuti CS, Dulley FL, Machado CM.

Acta Haematol. 2002;107(4):187-94.

PMID:
12053145
6.

Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial.

Winston DJ, Ho WG, Bartoni K, Du Mond C, Ebeling DF, Buhles WC, Champlin RE.

Ann Intern Med. 1993 Feb 1;118(3):179-84.

PMID:
8380243
7.

Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation.

Burns LJ, Miller W, Kandaswamy C, DeFor TE, MacMillan ML, Van Burik JA, Weisdorf DJ.

Bone Marrow Transplant. 2002 Dec;30(12):945-51.

8.

Cytotoxic T cells specific for cytomegalovirus: a potential therapy for immunocompromised patients.

Riddell SR, Reusser P, Greenberg PD.

Rev Infect Dis. 1991 Nov-Dec;13 Suppl 11:S966-73. Review.

PMID:
1664137
9.
10.

Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor.

Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, Thomas ED, Riddell SR.

N Engl J Med. 1995 Oct 19;333(16):1038-44.

11.

Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation.

Goodrich JM, Mori M, Gleaves CA, Du Mond C, Cays M, Ebeling DF, Buhles WC, DeArmond B, Meyers JD.

N Engl J Med. 1991 Dec 5;325(23):1601-7.

12.

Cytomegalovirus-specific T-cell immunity in recipients of autologous peripheral blood stem cell or bone marrow transplants.

Reusser P, Attenhofer R, Hebart H, Helg C, Chapuis B, Einsele H.

Blood. 1997 May 15;89(10):3873-9.

13.

Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant.

Goodrich JM, Bowden RA, Fisher L, Keller C, Schoch G, Meyers JD.

Ann Intern Med. 1993 Feb 1;118(3):173-8.

PMID:
8380242
14.

Reconstitution of HLA-A*2402-restricted cytomegalovirus-specific T-cells following stem cell transplantation.

Gondo H, Himeji D, Kamezaki K, Numata A, Tanimoto T, Takase K, Aoki K, Henzan H, Nagafuji K, Miyamoto T, Ishikawa F, Shimoda K, Inaba S, Tsukamoto H, Horiuchi T, Nakashima H, Otsuka T, Kato K, Kuroiwa M, Higuchi M, Shibuya T, Kamimura T, Kuzushima K, Tsurumi T, Kanda Y, Harada M.

Int J Hematol. 2004 Dec;80(5):441-8.

PMID:
15646657
15.

Effect of long-term prophylaxis in the development of cytomegalovirus-specific T-cell immunity in D+/R- solid organ transplant recipients.

San-Juan R, Navarro D, García-Reyne A, Montejo M, Muñoz P, Carratala J, Len O, Fortun J, Muñoz-Cobo B, Gimenez E, Eworo A, Sabe N, Meije Y, Martín-Davila P, Andres A, Delgado J, Jimenez C, Amat P, Fernández-Ruiz M, López-Medrano F, Lumbreras C, Aguado JM; REIPI Network.

Transpl Infect Dis. 2015 Oct;17(5):637-46. doi: 10.1111/tid.12417. Epub 2015 Aug 27.

PMID:
26134282
16.

Ganciclovir three times per week is not adequate to prevent cytomegalovirus reactivation after T cell-depleted marrow transplantation.

Przepiorka D, Ippoliti C, Panina A, Goodrich J, Giralt S, van Besien K, Mehra R, Deisseroth AB, Andersson B, Luna M, et al.

Bone Marrow Transplant. 1994 Apr;13(4):461-4.

PMID:
8019472
19.
20.

Polyfunctional cytomegalovirus-specific immunity in lung transplant recipients receiving valganciclovir prophylaxis.

Snyder LD, Medinas R, Chan C, Sparks S, Davis WA, Palmer SM, Weinhold KJ.

Am J Transplant. 2011 Mar;11(3):553-60. doi: 10.1111/j.1600-6143.2010.03405.x. Epub 2011 Jan 10.

Items per page

Supplemental Content

Write to the Help Desk